» Articles » PMID: 30258104

Fecal Microbiota Profile in a Group of Myasthenia Gravis Patients

Overview
Journal Sci Rep
Specialty Science
Date 2018 Sep 28
PMID 30258104
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The intestinal microbiota plays a key role in the maintenance of human health. Alterations in this microbiota have been described in several autoimmune diseases, including nervous system diseases. Nevertheless, the information regarding neuromuscular conditions is still limited. In this study, we aimed at characterizing the intestinal microbiota composition in myasthenia gravis patients (MG). To this end fecal samples were taken from ten patients, with antibodies against the acetylcholine receptor, and ten age and sex matched controls from the same population (Asturias region, Spain). Fecal samples were submitted to microbiota analyses by 16S rRNA gene profiling, bifidobacterial ITS-region profiling and qPCR. The fecal levels of short chain fatty acids were determined by gas chromatography. MG patients were found to harbor lower relative proportions of Verrucomicrobiaceae and Bifidobacteriaceae, among others, and increased of the phylum Bacteroidetes and the family Desulfovibrionaceae. The increase of these latter microbial groups was also confirmed at quantitative level by qPCR. In contrast, no statistically significant differences were found between MG patients and the control group in the bifidobacterial population at the species level or in short chain fatty acids profiles. Our data indicates an altered fecal microbiota pattern in MG patients and point out at specific microbiota targets for intervention in this population.

Citing Articles

Myasthenia gravis in 2025: five new things and four hopes for the future.

Binks S, Morse I, Ashraghi M, Vincent A, Waters P, Leite M J Neurol. 2025; 272(3):226.

PMID: 39987373 PMC: 11846739. DOI: 10.1007/s00415-025-12922-7.


Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis.

Deng X, Gong X, Zhou D, Hong Z Front Immunol. 2025; 16:1513599.

PMID: 39981228 PMC: 11839609. DOI: 10.3389/fimmu.2025.1513599.


Gut microbial profiles of patients with optic neuritis or myasthenia gravis.

Wu T, Jiang H, Lin C, Peng J, Kong X, Yu J J Int Med Res. 2025; 53(2):3000605251314817.

PMID: 39904582 PMC: 11795606. DOI: 10.1177/03000605251314817.


Explainable machine learning model for identifying key gut microbes and metabolites biomarkers associated with myasthenia gravis.

Chang C, Liu T, Lu C, Chiu H, Lin W Comput Struct Biotechnol J. 2024; 23:1572-1583.

PMID: 38650589 PMC: 11035017. DOI: 10.1016/j.csbj.2024.04.025.


Gut microbiota-derived butyrate restores impaired regulatory T cells in patients with AChR myasthenia gravis via mTOR-mediated autophagy.

He L, Zhong Z, Wen S, Li P, Jiang Q, Liu F Cell Commun Signal. 2024; 22(1):215.

PMID: 38570836 PMC: 10988943. DOI: 10.1186/s12964-024-01588-9.


References
1.
Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett W . Metagenomic biomarker discovery and explanation. Genome Biol. 2011; 12(6):R60. PMC: 3218848. DOI: 10.1186/gb-2011-12-6-r60. View

2.
Zheng H, Liang H, Wang Y, Miao M, Shi T, Yang F . Altered Gut Microbiota Composition Associated with Eczema in Infants. PLoS One. 2016; 11(11):e0166026. PMC: 5094743. DOI: 10.1371/journal.pone.0166026. View

3.
Burokas A, Moloney R, Dinan T, Cryan J . Microbiota regulation of the Mammalian gut-brain axis. Adv Appl Microbiol. 2015; 91:1-62. DOI: 10.1016/bs.aambs.2015.02.001. View

4.
Chen C, Chen K, Kong M, Chang H, Huang J . Alterations in the gut microbiotas of children with food sensitization in early life. Pediatr Allergy Immunol. 2015; 27(3):254-62. DOI: 10.1111/pai.12522. View

5.
Gilhus N, Skeie G, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S . Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016; 12(5):259-68. DOI: 10.1038/nrneurol.2016.44. View